Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-26
2006-12-26
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S269700
Reexamination Certificate
active
07153875
ABSTRACT:
The invention relates to certain heterocyclic compounds useful for the treatment of cancer and other diseases, having the Formula (I):wherein:(a) m is an integer 0 or 1;(b) R12is an alkyl, a substituted alkyl, a cycloalkyl, a substituted cycloalkyl, a heterocyclic, a substituted heterocyclic, a heteroaryl, a substituted heteroaryl, an aryl or a substituted aryl residue;(c) Ar3is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue;(d) Ar4is an aryl, a substituted aryl, a heteroaryl or a substituted heteroaryl residue;(e) R5is hydrogen, hydroxy, alkyl or substituted alkyl;(f) ----- represents a bond present or absent; and(g) W, X, Y and Z are independently or together —C(O)—, C(S), S, O, or NH;or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4051842 (1977-10-01), Hazel et al.
patent: 4140122 (1979-02-01), Kühl et al.
patent: 4383529 (1983-05-01), Webster
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa et al.
patent: 4788063 (1988-11-01), Fisher et al.
patent: 4931279 (1990-06-01), Bawa et al.
patent: 4948900 (1990-08-01), Iijima et al.
patent: 4971996 (1990-11-01), Shiraishi et al.
patent: 5223522 (1993-06-01), Clark et al.
patent: 5330998 (1994-07-01), Clark et al.
patent: 5512689 (1996-04-01), Quallich
patent: 5523314 (1996-06-01), Bue-Valleskey et al.
patent: 5650444 (1997-07-01), Cagiano et al.
patent: 5691376 (1997-11-01), Cagiano et al.
patent: 5780676 (1998-07-01), Boehm et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 6127415 (2000-10-01), Pfahl et al.
patent: 6262044 (2001-07-01), Møller et al.
patent: 6515003 (2003-02-01), Pfahl et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 6927228 (2005-08-01), Bernardon et al.
patent: 2003/0083357 (2003-05-01), Pfahl et al.
patent: 2003/0105333 (2003-06-01), Pfahl et al.
patent: 2003/0144329 (2003-07-01), Pfahl et al.
patent: 2003/0153606 (2003-08-01), Pfahl et al.
patent: 2003/0216432 (2003-11-01), Pfahl et al.
patent: 2004/0034004 (2004-02-01), Pfahl et al.
patent: 2004/0097566 (2004-05-01), Pfahl et al.
patent: 0 212 617 (1987-03-01), None
patent: 0 304 493 (1989-03-01), None
patent: 0 343 643 (1989-11-01), None
patent: 1 048 659 (2000-11-01), None
patent: 1 142 885 (2001-10-01), None
patent: 55 038359 (1980-03-01), None
patent: WO 93/21146 (1993-10-01), None
patent: WO 94/12880 (1994-06-01), None
patent: WO 97/00249 (1997-01-01), None
patent: WO 97/03682 (1997-02-01), None
patent: WO 97/27191 (1997-07-01), None
patent: WO 99/09965 (1999-03-01), None
patent: WO 99/24415 (1999-05-01), None
patent: WO 99/58127 (1999-11-01), None
patent: WO 00/10573 (2000-03-01), None
patent: WO 00/18748 (2000-04-01), None
patent: WO 00/32598 (2000-06-01), None
patent: WO 00/63196 (2000-10-01), None
patent: WO 00/66167 (2000-11-01), None
patent: WO 01/16122 (2001-03-01), None
patent: WO 01/16123 (2001-03-01), None
patent: WO 01/36402 (2001-05-01), None
patent: WO 02/12210 (2002-02-01), None
patent: WO 02/071827 (2002-09-01), None
patent: WO 02/072009 (2002-09-01), None
patent: WO 02/072543 (2002-09-01), None
patent: WO 02/080935 (2002-10-01), None
patent: WO 2004/113331 (2004-12-01), None
Strandtmann et al. , J. Med. Chem. (1967), 10(6);1063-1065.
Sof'ina et al. Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations. NCI Monograph 55. NIH Publication No. 80-1933 (1980).
Singh et al. Indian Drugs (1985), 22(10) : 519-23.
Alley et al., “Feasibility of Drug Screening with Panels of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay,”Cancer Res. 48:589-601 (1988).
Amin et al., “Nitric Oxide Synthase and Cyclooxygenases: Distribution, Regulation, and Intervention in Arthritis,”Nitric pin. Rheumatol, 11(3):202-209 (1999).
Aranyos et al., “Novel Electron-Rich Bulky Phospine Ligands Facilitate the Palladium-Catalyzed Preparation of Diaryl Ethers,”J. Am. Chem. Soc. 121:4369-4378 (1999).
Baraldi et al., “Exhaled Nitric Oxide Concentrations During Treatment of Wheezing Exacerbation in Infants and Young Children,”Am. J. Respir. Crit. Care Med., 159 (4 Pt. 1):1284-1288 (1999).
Beilstein Registry No. 29-30, 1975, Compound Registry No. 1120438.
Beilstein Registry No. 52, 1978, Compound Registry No. 4939128.
Black, “Simple Synthesis of 1-Azaadamantan-4-one,”Synthesis829-830 (1981).
Bradisher et al., “Aromatic Cyclodehydration XXIV. Cyclization of Derivatives of (2-biphenylly)pyruvic Acid,”J. Org. Chem., 15(2) 374-376 (1950).
Bredt et al., “Isolation of Nitric Oxide Synthetase, a Calmodulin-Requiring Enzyme,”Proc. Natl. Acad. Sci. 87:682-685 (1990).
Brennan et al., “Inhibitory Effect of TNFα Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis,”Lancet, 2:244-247 (1989).
Chan et al., “New N- and O-Arylations with Phenyloboronic Acids and Curpric Acetate,”Tetrahedron Letters39:2933-2936 (1998).
Charpentier et al., “Synthesis, Structure—Affinity Relationships, and Biological Activities of Ligands Binding to Retinoic Acid Receptor Subtypes,”J. Med. Chem. 38:4993-5006 (1995).
Choi et al., “Similarity of Colorectal Cancer in Crohn's Disease and Ulcerative Colitis: Implications for Carcinogenesis and Prevention,” Gut, 35:950-954 (1994).
Cobb et al., “N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent,”J. Med. Chem. 41:5055-5069 (1998).
Darses et al., “Palladium-Catalyzed Cross-Coupling Reactions of Arenediazonium Tetrafluoroborates with Aryl- and Alkenylboronic Acids,”Bull. Soc. Chem. Fr., 133:1095-1102 (1996).
Ebisawa et al., “Novel Thiazolidinedione Derivatives with Retinoid Synergistic Activity,”Biol. Pharma. Bull., 21(5):547-549 (1998).
Evans et al., “Synthesis of Diaryl Ethers through the Cooper-Promoted Arylation of Phenols with Arylboronic Acids. An Expedient Synthesis of Thyroxine,”Tetrahedron Letters39:2937-2940 (1998).
Farahat et al., “Cytokine Epression in Synovial Membranes of Patients with Rheumatoid Arthritis and Osteoarthritis,”Ann. Rheum. Dis., 52: 870-875 (1993).
Ferrell, “Tripping the Switch Fantastic: How A Protein Kinase Cascade Can Convert Graded Inputs into Switch-Like Outputs,”TIBS, 21:460-466 (1996).
Firooznia et al., “Enantioselective Synthesis of 4-Substituted Phenylalanines By Cross-Coupling Reactions,”Tetrahedron Letters, 40:213-216 (1999).
Förstermann et al., “Induced RAW 264.7 Macrophages Express Soluble and Particulate Nitric Oxide Synthase: Inhibition By Transforming Growth Factor-β,”Eur. J. Pharm., 225:161-165 (1992).
Fukuto et al., “Inhibition of Constitutive and Inducible Nitric Oxide Synthase: Potential Selective Inhibition,”Annu. Rev. Pharmacol. Toxicol. 35:165-194 (1995).
Gahtan et al., “Inflammatory Pathogenesis in Alzheimer's Disease: Biological Mechanisms and Cognitive Sequeli,”Neurosci: Biobehav, 23:615-633 (1999).
Glauser et al., “Pathogenesis and Potential Strategies for Prevention and Treatment of Septic Shock: An Update,”Clin. Infect Dis. 18 (Suppl. 2):S205-216 (1994).
Haddach et al., “A New Method for the Synthesis of Ketones: The Palladium-Catalyzed Corss-Coupling of Acid Chlorides with Arylboronic Acids,”Tetrahedron Letters40:3109-3112 (1999).
Harris et al., “Localization of a Pioglitazone Response Element in the Adipocyte Fatty Acid-Binding Protein Gene,”Mol. Pharmacol. 45:439-445 (1994).
Hudlicky, “Oxidations in Organic Chemistry,” ACS Monograph 186:114-127 (1990).
Hudlicky, “Oxidations in Organic Chemistry,” ACS Monograph 186:133-149 (1990).
Indolese, “Suzuki-Type Coupling of Chloroarenes with Arylboronic Acids Catalysed by Nickel Complexes,”Tetrahedron Letters, 38:3513-3516 (1997).
Ishiyama et al., “Palladium(0)-Catalyzed Cross-Coupling Reaction of Alkoxydiboron
Al-Shamma Hussien A.
Fanjul Andrea
Ibarra Jason B.
Pfahl Magnus
Pleynet David P.M.
Davis Zinna N.
Incyte San Diego
Needle & Rosenberg P.C.
LandOfFree
Heterocyclic derivatives for the treatment of cancer and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic derivatives for the treatment of cancer and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic derivatives for the treatment of cancer and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3688518